Skip to content

Study · Not a test of the peptide alone · 1996

3 results

Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.

Bhardwaj R, Blanchard J

Journal of pharmaceutical sciences1 Sept 1996Cited by 94 (Europe PMC)

PMID8877878 (opens in a new tab)DOI10.1021/js960097g (opens in a new tab)PepBankPUB-08877878
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In guinea pigs given intraperitoneal doses, MT-I formulated in poloxamer gel showed extended release in plasma compared with MT-I in solution.

    In plain wordsIn guinea pigs, MT-I in a gel stayed in the blood longer than MT-I given as a plain solution.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePlasma concentration-time profile of MT-I from gel versus solution
    Study

    guinea pign: not reported in source

    Comparator
    MT-I in solution
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The plasma concentration-time profiles showed an extended release of the peptide formulated with gel compared to the intraperitoneal administration of MT-I in solution.
    2 context sentences
    Summary · context
    The in-vivo release kinetics of selected formulations were analyzed in guinea pigs following intraperitoneal administration.
    Summary · context
    The overall objective of these studies was to develop a controlled-release formulation of Melanotan-I (MT-I) containing poloxamer 407 (P407).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    In an in-vitro model, poloxamer 407 formulations of MT-I with PVP accelerated gel dissolution and peptide release compared with the control formulation.

    In plain wordsIn lab tests, adding PVP to the MT-I gel made the gel dissolve and release the peptide faster than the control gel.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseGel dissolution and MT-I release with PVP
    Study

    n: not reported in source

    membraneless in-vitro release model
    Comparator
    Control poloxamer 407 formulation
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    It was observed that the PVP-containing P407 formulations of MT-I accelerated the dissolution of gel and the release of the peptide compared to the control formulation.
    1 context sentence
    Summary · context
    The overall objective of these studies was to develop a controlled-release formulation of Melanotan-I (MT-I) containing poloxamer 407 (P407).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    In an in-vitro model, poloxamer 407 formulations of MT-I with MC or HPMC showed the slowest dissolution rates and MT-I release.

    In plain wordsIn lab tests, adding MC or HPMC to the MT-I gel gave the slowest dissolving gels and the slowest peptide release.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGel dissolution and MT-I release with MC or HPMC
    Study

    n: not reported in source

    membraneless in-vitro release model
    Comparator
    Other poloxamer 407 formulations
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The formulations containing MC or HPMC exhibited the slowest dissolution rates and release of MT-I.
    1 context sentence
    Summary · context
    The overall objective of these studies was to develop a controlled-release formulation of Melanotan-I (MT-I) containing poloxamer 407 (P407).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.